A Study of HLD-0117 in Patients With Metastatic Breast Cancer

Halda Therapeutics OpCo, Inc.

Status and phase

Enrolling

Phase 1

Conditions

Metastatic Breast Cancer

Treatments

Drug: HLD-0117

Study type

Interventional

Funder types

Industry

Identifiers

NCT07524855

HLD-0117-ONC-101

Details and patient eligibility

About

Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed on prior systemic therapies.

Full description

This study is an open-label, dose-escalation and cohort expansion study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of oral single-agent, HLD-0117 in patients with ER+ MBC that have progressed after at least 1 prior systemic line of therapy.

During dose escalation, patients will be enrolled into monotherapy cohorts using a Bayesian optimal interval (BOIN) design. Cohorts will enroll a minimum of three patients, with staggered enrollment between cohorts. Backfilling into dose levels determined to be safe may occur to further characterize tolerability and efficacy.

The purpose of the study is to determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDEs) of HLD-0117 as a monotherapy.

Enrollment

33 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Female (assigned at birth), ≥18 years old, and able to provide informed consent
Histologically confirmed metastatic or locally advanced breast cancer
Postmenopausal status defined by surgical or natural menopause, or ovarian suppression with a GnRH agonist
Prior treatment including at least one endocrine therapy in the metastatic setting, at least one CDK4/6 inhibitor (in the adjuvant and/or metastatic setting), and no more than two prior cytotoxic regimens in the metastatic setting
Radiologic disease progression on the most recent therapy
Measurable disease per RECIST v1.1
Willingness to provide baseline and on-treatment tumor biopsies, unless not feasible or medically appropriate
ER-positive and HER2-negative status documented within 2 years
ECOG performance status 0-1 and life expectancy of at least 3 months
Adequate organ function Recovery from prior therapy-related toxicities to Grade ≤1 (except alopecia; neuropathy and endocrinopathies ≤Grade 2)
Ability to swallow oral medication and comply with study procedures
Stable dose (≥30 days) of bisphosphonates or denosumab, if applicable

Exclusion criteria

Inflammatory breast cancer or known brain metastases
Recent major bleeding or uncontrolled bleeding disorder
Ongoing corticosteroid use >10 mg/day (prednisone equivalent)
Recent anticancer or investigational therapy within 14 days (28 days for fulvestrant)
Untreated or unstable spinal cord compression
Significant cardiovascular disease within 6 months or ongoing uncontrolled cardiac conditions
Active or uncontrolled infection (controlled HIV or treated hepatitis C allowed)
Uncontrolled renal, pancreatic, or liver disease (excluding stable conditions such as Gilbert's syndrome or liver metastases)
Another malignancy requiring treatment within 2 years (except low-risk, curatively treated cancers)
Major surgery within 28 days
Any condition that may interfere with safety or study compliance
Pregnancy or breastfeeding